Insomnia Market Overview:

Global Insomnia Market was valued at $4,093 million in 2016, and is estimated to reach $5,488 million by 2023, registering a CAGR of 4.2% from 2017 to 2023. Insomnia is a sleep disorder where in the person faces difficultly to sleep or remain asleep. The symptoms include low stamina, daytime sleepiness, depression, and irritability. It is a highly prevalent disorder that affects millions of people, worldwide. Insomnia-related conditions are caused due to disruption in circadian rhythm, chronic pain, hyperthyroidism, menopause, psychological stress, and other medical conditions. Moreover, excessive use of drugs, such as caffeine, alcohol, and nicotine could lead to insomnia. This disorder can be diagnosed in sleep laboratories using various diagnostic devices. Depending on the duration of the disorder, insomnia is divided into three types, namely transient, acute, and chronic insomnia. In transient insomnia, the symptoms persist from a few days to a few weeks; acute insomnia persists for several weeks; and chronic insomnia last for months to a few years.

Global Insomnia Market Segmentation

The global insomnia market is segmented based on therapy type and geography. Based on therapy type, it is bifurcated into non-pharmacological and pharmacological therapy. Non-pharmacological therapy is further categorized into hypnotherapy, cognitive behavioral therapy, medical devices, and other non-pharmacological therapy. Pharmacological therapy is further divided into prescription sleep aids and over-the-counter sleep aids. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Drivers, Restraints, and Opportunities

The impact of the driving factors is expected to surpass the effect of restraints. Moreover, technological advancements have led to higher adoption rate and untapped markets in the developing economies are expected to provide new avenues for the growth of the insomnia market in the near future.

Drivers and Restraints

Global Insomnia Market: Key Geographical Segments

North America accounted for the highest market share in the insomnia market in 2016, and is expected to maintain its dominance throughout the forecast period.

The other prominent players in the value chain include Fidia Farmaceutici, Dainippon Sumitomo, Biocodex, Eli Lilly and Company, and Ebb Therapeutics.

Key Benefits

This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.

Market estimations are based on comprehensive analysis of the key developments in the industry.

The global market is comprehensively analyzed with respect to therapy type and geography.

In-depth analysis based on geography assists in understanding the regional market to assist in strategic business planning.

The growth strategies adopted by key manufacturers assist in understanding the competitive scenario of the market.

Insomnia Market Key Segments:

By Therapy Type

Non-pharmacological Therapy

Hypnotherapy

Cognitive Behavioral Therapy

Medical Devices

Other Non-pharmacological Therapy

Pharmacological Therapy

Prescription Sleep Aids

Over-the-counter Sleep Aids

By Geography

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Spain

Rest of Europe

Asia-Pacific

Japan

China

Australia

India

Rest of Asia-Pacific

LAMEA

Brazil

Republic of South Africa

Saudi Arabia

Rest of LAMEA

Table Of Contents

Shoping Basket

PRODUCT

QUANTITY

PRICE

* Pricing on the website is provided for single users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at +1-800-792-5285 or send an email to sales@alliedmarketresearch.com

Insomnia is a sleep disorder caused due to various factors such as stressful lifestyle, mental disorders, and other medical conditions, consumption of certain drugs, caffeine, and alcohol also cause insomnia. The therapeutic techniques differ with the type of insomnia affecting the quality of sleep of the patient. The types of insomnia differ with the duration the disorder, such as: transient (persist for few days), acute (few weeks), and chronic (few months).

The rise in demand for over-the-counter (OTC) sleep aids and emergence of therapeutics with fewer side-effects drive the market growth. In addition, rise in geriatric population and growth in the incidence rate of chronic diseases are increased the use of therapeutics for treating insomnia. Furthermore, the rise in stress level among youth due to factors such as job stress and intense competition have led to surge in the incidence rate of insomnia. However, the side-effects caused due to excessive use of sleep medication and patent expiration of various prescription drugs are expected to restrict the market growth.

Non-pharmacological therapy segment is expected to be lucrative for new entrants and existing market players, as this form of treatment causes fewer side-effects as compared to sleep medications. Furthermore, cognitive behavioral therapy is expected to be the fastest growing segment in the near future, as these therapies help to identify and change the thought and behavior that causes insomnia in a patient. Moreover, in this technique, therapeutic approach can be modified as per the needs of patients.

The use of insomnia treatment is highest in North America, owing to increase in adoption of these therapies, high prevalence rate of insomnia, and rise in disposable income among customers. Although the use of therapies for the treatment of insomnia is low in Asia-Pacific and LAMEA, the adoption rate is expected to increase due to rise in disposable income, increase in incidence rate of insomnia, and surge in the number of people working at odd hours.

License Type

Online Only

Data Pack/Excel

Single User

Five User Online

Enterprise Online

LICENSE INFO

Users/Sharing

Restricted to one authorized user

Restricted to one authorized user

Restricted to one authorized user

Limited to 5 authorized users

Unlimited within company / enterprise

Printing

No Print/No Copy/No Screenshot

One Print only

One Print only

Up to Five Copies

Unlimited within company / enterprise

Delivery Formats

ADDED BENIFITS

20% Free customization (Pre-sale)

16 Analyst hour support
(Post Sale)

40 Analyst hour support
(Post Sale)

160 hours of mini-consult

Free quarterly industry update

Free report on update (within 180 days)

MULTIPLE PURCHASE

Complimentary report with 2 reports

Complimentary report with 3 reports

Subscription Model

Get More Information About this Report

Let us know more about your research need and we will customize an offer exclusively for you!